1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Haemophilus influenza (Hib)- Type B Infection Drug Development Pipeline Study, H2 2018

Haemophilus influenza (Hib)- Type B Infection Drug Development Pipeline Study, H2 2018

  • August 2018
  • 60 pages
  • ID: 5483465
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies

Haemophilus influenza (Hib) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Haemophilus influenza (Hib) Infection pipeline products.

DISEASE OVERVIEW
Haemophilus influenza bacteria (Hib) often causes various types of infections ranging from mild to serious levels such as infections in skin, ear infections, lungs, blood, Meningitis, Epiglotittis etc. Maximum incidence of the infection is observed among young children.

Haemophilus influenza is classified into two types- unencapsulated and encapsulated , which are further divided into different serotypes. Of these the serotype b accounts for 95% of all invasive infections caused by the bacteria.

As these infections are similar to the ones caused by other bacteria, quick and accurate diagnosis is challenging. Mass vaccination programs are being conducted to prevent the spread of Hib infections. Cephalosporins are primarily administered to patients infected with the bacteria.

15+ companies are currently participating in the pipeline development of Haemophilus influenza bacterial infection pipeline (Hib) including Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Novo Medi Sciences Pvt Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi Pasteur SA, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.

REPORT DESCRIPTION
The Haemophilus influenza (Hib) Infection pipeline guide presents complete overview of drugs currently being developed for Haemophilus influenza (Hib) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Haemophilus influenza (Hib) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Haemophilus influenza (Hib) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Haemophilus influenza (Hib) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Haemophilus influenza (Hib) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Haemophilus influenza (Hib) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Haemophilus influenza (Hib) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Haemophilus influenza (Hib) Infection pipeline report includes
- Panorama of Haemophilus influenza (Hib) Infection pipeline markets including statistics on therapeutic drugs and companies involved

- Haemophilus influenza (Hib) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

- Haemophilus influenza (Hib) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study

- Overview of companies participating in Haemophilus influenza (Hib) Infection pipeline with short introduction to their businesses and pipeline projects

- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

- Research and Development progress and trial details, results wherever available, are also included in the pipeline study

- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Haemophilus influenza (Hib) Infection pipeline therapeutics

Reasons to Buy
- Get clear understanding of the entire Haemophilus influenza (Hib) Infection pipeline, with details on active projects

- Get in detail information of each product with updated information on each project along with key milestones

- Know the list of companies participating in global Haemophilus influenza (Hib) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data

- Get trial information for each pipeline product under development

- Understand the pipeline structure in terms of mechanism of Action, phase and company

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Influenza Diagnostics Market by Product, End User, Region-Global Forecast to 2026

  • $ 4950
  • September 2021
  • 188 pages

The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8billion in 2021, at a CAGR of 7.7% during the forecast period. Market growth is driven by factors such ...

  • World
  • United States
  • Diagnostics
  • Influenza
  • Industry analysis
  • Influenza Prevalence
  • Health Expenditure

ref:plp2018

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on